Kasaraki tablet 32mg #30

Form

tableti

Dosage mg

32

Pack

30

CASARKI TABLET 32MG Composition: Active substance: candesartan cilexetil; 1 tablet contains candesartan cilexetil, calculated as 100% substance, 32 mg. Excipients: carmellose calcium; corn starch; hydroxypropylcellulose; lactose, monohydrate; magnesium stearate; polyethylene glycol (PEG 8000) Indications: Treatment of essential hypertension in adults; Treatment of hypertension in children and adolescents aged 6 to 18 years; Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤ 40%), as add-on therapy to ACE inhibitors or in cases of ACE inhibitor intolerance. Contraindications: Hypersensitivity to candesartan cilexetil or any of the excipients; Severe hepatic impairment and/or cholestasis; Use during the second or third trimester of pregnancy; Children under 1 year of age; Concomitant use of ACE inhibitors or angiotensin II receptor antagonists with preparations containing aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (eGFR < 60 ml/min/1.73 m²). Dosage and administration Hypertension The recommended starting and maintenance dose of CASARKI is 8 mg once daily. The main antihypertensive effect is achieved within 4 weeks of starting treatment. If blood pressure is not adequately controlled, the dose may be increased to 16 mg once daily and up to a maximum of 32 mg once daily. Treatment should be adjusted according to blood pressure. Renal impairment. For patients with renal impairment, as well as patients on hemodialysis, the starting dose is 4 mg once daily. The dose should be titrated according to clinical response. There is limited experience in patients with very severe renal impairment or renal failure (creatinine clearance < 15 ml/min). Hepatic impairment. A starting dose of 4 mg once daily is recommended for patients with mild to moderate hepatic impairment. Dose adjustment is based on clinical response. CASARKI is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections "Contraindications" and "Pharmacokinetics"). Children and adolescents aged 6 to 18 years. The recommended starting dose of the preparation is 4 mg once daily. - For patients with a body weight < 50 kg: For patients with unsatisfactory blood pressure control, the dose may be increased to a maximum of 8 mg once daily. - For patients with a body weight ≥ 50 kg: For patients with unsatisfactory blood pressure control, the dose may be increased to 8 mg once daily and then, if necessary, to 16 mg once daily. Storage: In the original packaging at a temperature not exceeding 25° C. Keep out of reach of children.